November 20, 2025

Alkermes reports messy Phase 2 narcolepsy data, stock drops

IntelME Verdict

Mixed Results

TL;DR

Alkermes' Phase 2 results show alixorexton's efficacy in narcolepsy type 2, meeting primary endpoints with improved sleep measures, prompting Phase 3 trials, despite stock drop.

Analysis

The positive Phase 2 results of alixorexton in narcolepsy type 2, despite the stock drop, indicate potential efficacy in improving sleep measures. This matters to healthcare providers as it signals a new treatment option for managing NT2, potentially impacting clinical practice and patient outcomes.

Source

Endpoints News↗